Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells

Annals of the New York Academy of Sciences

Volumn 1095, Issue , 2007, Pages 26-34

  Song, Yoo Cheol ^a   Kim, Su Hyeong ^a   Juhnn, Yong Sung ^a   Song, Yong Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Caspase; Celecoxib; NSAIDs; Ovarian cancer; p53

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CELECOXIB; DEATH RECEPTOR; PROTEIN P53; ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; MUTATION RATE; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; ARTICLE; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GROWTH INHIBITORS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PYRAZOLES; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247895515     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1397.004     Document Type: Conference Paper

References (29)

1. TAKIKO, D. et al. 2005. Cyclooxygenase-1 is a potential, target for prevention and treatment of ovarian, epithelial cancer. Cancer Res. 65: 3735-3744.
2. CHOE, M.S. et al. 2005. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. 4: 1448-1455.
3. REESE, J. et al. 2001. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 142: 3198-3206.
4. ARAKI, Y. et al. 2003. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63: 728-734.
5. JEON, Y.T. et al. 2004. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 13: 1538-1542.
6. SUBHASHINI, J. et al. 2005. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 224: 331-343.
7. LIU, X. et al. 2004. Death receptor regulating and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 96: 1769-1780.
8. DEVENDRA, S.D. et al. 2005. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 115: 484-492.
9. DIN, F.V.N. et al. 2005. Aspirin-induced nuclear translocation of NFκB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br. J. Cancer 92: 1137-1143.
10. JACOBS, I. et al. 1993. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306: 1030-1034.
11. AUERSPERG, N. et al. 2001. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22: 255-288.
12. ZUCO, V. et al. 2004. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ. 11: 280-289.
13. FLESKEN-NIKITIN, A. et al. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63: 3459-3463.
14. SEO, S.S. et al. 2004. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol. 92: 927-935.
15. LIN, H.P. et al. 2004. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol. Cancer Ther. 3: 1671-1680.
16. SAWAKOA, H. et al. 1998. Effects of NSAIDs on proliferation of gastric cancer in vitro: possible implication of cyclooxygenase-2 in cancer development. J. Clin. Gastroenterol. 27: 47-52.
17. KIM, S.H. et al. 2004. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J. Cancer Res. Clin. Oncol. 130: 551-560.
18. SONG, S.H. et al. 2001. Transcriptional silencing of cyclooxygenase-2 by hypermethylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res. 61: 4628-4635.
19. RODRIGUEZ-BURFORD, C. et al. 2002. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin. Cancer Res. 8: 202-209.
20. LOPEZ-GONZALEZ, J.S. et al. 2004. Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer 43: 275-283.
21. ANNA, T. et al. 2005. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J. Transl. Med. 3: 7-16.
22. TEGEDER, T. et al. 2001. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15: 2057-2072.
23. CASTANO, E. et al. 1999. Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br. J. Cancer 81: 294-299.
24. YIM, H.W. et al. 2005. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res. 65: 1952-1960.
25. TEOH, G. et al. 2000. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 95: 1039-1046.
26. PRITCHARD, D.M. et al. 1997. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA 94: 1795-1799.
27. SONG, X. et al. 2002. Cyclooxygenase-2 player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94: 585-591.
28. WASKEWICH, C. et al. 2002. Celecoxib exhibits the greatest potency amongst cyclooxygenase inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62: 2029-2033.
29. AGARWAL, R. et al. 2003. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3: 502-516.